ESBATech AGSuccess through highly stable antibody fragments
The Company Products & Technologies PR and Publications Career

About ESBATech
People
Intellectual Property
Directions
Contact

Drug Discovery
Drug Development
Company News
Scientific Publications
Upcoming Events
PR Contact
Why ESBATech
Positions
To apply
Webmail
 

ESBATech, an Alcon Biomedical Research Unit


 

ESBATech is a Zurich, Switzerland based Biomedical Research Unit of Alcon. The company has been acquired by Alcon, the world leader in Ophthalmology, on September 14, 2009. ESBATech lays the foundation for Alcon to move into biotechnology. Prior to the acquisition, ESBATech focused on advancing therapeutic antibody fragments in ophthalmology but also other fields. All rights outside of ophthalmology were spun-out to Delenex Therapeutics.

 

 
 

Latest Company News

HUENENBERG and ZURICH, Switzerland – September 14, 2009
Alcon to Acquire Swiss Biotechnology Firm, ESBATech AG

>> read complete press release

Zurich, Switzerland; March 24, 2009
Topical ESBA105 Demonstrates Efficacy in the Back of the Eye to Inhibit Neovascularization

>> read complete press release

Zurich, Switzerland; February 24, 2009
ESBATech’s Antibody Fragment ESBA105 Enters Phase IIa in Uveitis Study

>> read complete press release

Zurich, Switzerland; February 3, 2009
ESBATech's Antibody Fragment Enters Phase Ib/IIa in Ophthalmology

>> read complete press release

Mountain View, California; January 26, 2009
Frost & Sullivan Recognizes ESBATech’s Innovation in Developing Antibody Fragments for Biologic Therapeutics

>> read complete press release

 

 
 
ESBATech
Wagistrasse 21
CH-8952
Zurich-Schlieren
Switzerland

 
Disclaimer
©  ESBATech